Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

New Biomarker May Predict Risk for Uterine Cancer Recurrence

Web Exclusives

Endometrial cancer is one type of uterine cancer and is the most common gynecologic cancer in Europe and in North America.

New Biomarker

Researchers at the universities in Uppsala, Sweden; Turku, Finland; and Bergen, Norway, were able to identify patients who are at increased risk for recurrence based on the amount of ASRGL1 present in the patient’s tumor cells. This newly found biomarker, ASRGL1, is a type of protein that is typically found in healthy uterine cells.

The researchers found that patients who had higher levels of ASRGL1 in their uterine cells had a much lower risk for the cancer returning than those with little to no ASRGL1 in their cells.

ASRGL1 was also found to be an independent prognostic factor that is not related to the stage or grade of the tumor.

What This Means for the Future

Results of the study indicate that ASRGL1 could eventually be used as a diagnostic tool to identify women who may need more extensive treatment because of their higher risk for uterine cancer recurrence, but more research is needed.

Additional studies are already being planned to determine if ASRGL1 can also be used for diagnosing tissue biopsies before surgery.

Full article: www.sciencedaily.com/releases/2015/04/150414083720.htm

Patient Resources

American Cancer Society
www.cancer.org/cancer/uterinesarcoma/
National Cancer Institute
www.cancer.gov/cancertopics/types/uterine

Recommended For You